199 related articles for article (PubMed ID: 31219558)
21. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
22. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.
Dichtel LE; Carpenter LL; Nyer M; Mischoulon D; Kimball A; Deckersbach T; Dougherty DD; Schoenfeld DA; Fisher L; Cusin C; Dording C; Trinh NH; Pedrelli P; Yeung A; Farabaugh A; Papakostas GI; Chang T; Shapero BG; Chen J; Cassano P; Hahn EM; Rao EM; Brady RO; Singh RJ; Tyrka AR; Price LH; Fava M; Miller KK
Am J Psychiatry; 2020 Oct; 177(10):965-973. PubMed ID: 32660299
[TBL] [Abstract][Full Text] [Related]
23. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial.
Spettigue W; Buchholz A; Henderson K; Feder S; Moher D; Kourad K; Gaboury I; Norris M; Ledoux S
BMC Pediatr; 2008 Jan; 8():4. PubMed ID: 18234120
[TBL] [Abstract][Full Text] [Related]
25. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial.
Davis S; Papalia MA; Norman RJ; O'Neill S; Redelman M; Williamson M; Stuckey BG; Wlodarczyk J; Gard'ner K; Humberstone A
Ann Intern Med; 2008 Apr; 148(8):569-77. PubMed ID: 18413618
[TBL] [Abstract][Full Text] [Related]
27. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
[TBL] [Abstract][Full Text] [Related]
28. The sexual effects of testosterone replacement in depressed men: randomized, placebo-controlled clinical trial.
Seidman SN; Roose SP
J Sex Marital Ther; 2006; 32(3):267-73. PubMed ID: 16809253
[TBL] [Abstract][Full Text] [Related]
29. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression.
Feighner J; Targum SD; Bennett ME; Roberts DL; Kensler TT; D'Amico MF; Hardy SA
J Clin Psychiatry; 1998 May; 59(5):246-53. PubMed ID: 9632036
[TBL] [Abstract][Full Text] [Related]
30. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
Rickels K; Mathew S; Banov MD; Zimbroff DL; Oshana S; Parsons EC; Donahue SR; Kauffman M; Iyer GR; Reinhard JF
J Clin Psychopharmacol; 2008 Apr; 28(2):235-9. PubMed ID: 18344738
[TBL] [Abstract][Full Text] [Related]
31. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
Liebowitz MR; Yeung PP; Entsuah R
J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
[TBL] [Abstract][Full Text] [Related]
32. St. John's wort extract LI160 for the treatment of depression with atypical features - a double-blind, randomized, and placebo-controlled trial.
Mannel M; Kuhn U; Schmidt U; Ploch M; Murck H
J Psychiatr Res; 2010 Sep; 44(12):760-7. PubMed ID: 20181361
[TBL] [Abstract][Full Text] [Related]
33. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study.
Bielski RJ; Cunningham L; Horrigan JP; Londborg PD; Smith WT; Weiss K
J Clin Psychiatry; 2008 Apr; 69(4):571-7. PubMed ID: 18373383
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder.
Khan A; Joyce M; Atkinson S; Eggens I; Baldytcheva I; Eriksson H
J Clin Psychopharmacol; 2011 Aug; 31(4):418-28. PubMed ID: 21694613
[TBL] [Abstract][Full Text] [Related]
35. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
36. Testosterone administration in women with anorexia nervosa.
Miller KK; Grieco KA; Klibanski A
J Clin Endocrinol Metab; 2005 Mar; 90(3):1428-33. PubMed ID: 15613421
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR;
J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
[TBL] [Abstract][Full Text] [Related]
38. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial.
Bissada H; Tasca GA; Barber AM; Bradwejn J
Am J Psychiatry; 2008 Oct; 165(10):1281-8. PubMed ID: 18558642
[TBL] [Abstract][Full Text] [Related]
39. A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression.
Richards EM; Mathews DC; Luckenbaugh DA; Ionescu DF; Machado-Vieira R; Niciu MJ; Duncan WC; Nolan NM; Franco-Chaves JA; Hudzik T; Maciag C; Li S; Cross A; Smith MA; Zarate CA
Psychopharmacology (Berl); 2016 Mar; 233(6):1119-30. PubMed ID: 26728893
[TBL] [Abstract][Full Text] [Related]
40. An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD).
Cutler NR; Sramek JJ; Macpherson AE; Doss MG; Benes CO; Howard SF
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):685-94. PubMed ID: 7938559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
